A phase I COVID-19 vaccine trial among SARS-CoV-2 seronegative and seropositive individuals in Uganda utilizing a self-amplifying RNA vaccine platform: Screening and enrollment experiences.
Saved in:
| Title: | A phase I COVID-19 vaccine trial among SARS-CoV-2 seronegative and seropositive individuals in Uganda utilizing a self-amplifying RNA vaccine platform: Screening and enrollment experiences. |
|---|---|
| Authors: | Kitonsa J; Medical Research Council/Uganda Virus Research Institute, London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda., Kamacooko O; Medical Research Council/Uganda Virus Research Institute, London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda., Ruzagira E; Medical Research Council/Uganda Virus Research Institute, London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda., Nambaziira F; Medical Research Council/Uganda Virus Research Institute, London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda., Abaasa A; Medical Research Council/Uganda Virus Research Institute, London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda.; Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK., Serwanga J; Medical Research Council/Uganda Virus Research Institute, London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda., Gombe B; Medical Research Council/Uganda Virus Research Institute, London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda., Lunkuse J; Medical Research Council/Uganda Virus Research Institute, London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda., Naluyinda H; Medical Research Council/Uganda Virus Research Institute, London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda., Tukamwesiga N; Medical Research Council/Uganda Virus Research Institute, London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda., Namata T; Medical Research Council/Uganda Virus Research Institute, London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda., Kigozi A; Medical Research Council/Uganda Virus Research Institute, London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda., Kafeero P; Medical Research Council/Uganda Virus Research Institute, London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda., Basajja V; Medical Research Council/Uganda Virus Research Institute, London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda., Joseph S; Department of Infectious Disease, Imperial College London, London, UK., Pierce BF; Department of Infectious Disease, Imperial College London, London, UK., Shattock R; Department of Infectious Disease, Imperial College London, London, UK., Kaleebu P; Medical Research Council/Uganda Virus Research Institute, London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda. |
| Source: | Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2023 Aug 01; Vol. 19 (2), pp. 2240690. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
